EXTENDED RELEASE
FOR EXTENDED RELIEF
New ZILRETTA
NDC Number
65250-0003-01
FOR EXTENDED RELIEF
Explore ZILRETTA and learn why it may be right for your patients experiencing OA knee pain.
LOCAL
RAPID
PERSISTENT
SAFETY
*Defined as time from IA injection to the first daily pain assessment of >30% improvement from baseline.
When we differentiated intra-articular corticosteroids extended versus immediate release... (Bodick 2015, Conaghan 2018, and Langworthy 2019), our analyses demonstrated that, extended release IA steroids can be used over immediate release to improve patient outcomes. 6†
American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Knee (Non-Arthroplasty) Evidence-Based Clinical Practice Guideline
†Moderate strength recommendation. Evidence from two or more “Moderate” quality studies with consistent findings, or evidence from a single “High” quality study for recommending for or against the intervention. Also requires no or only minor concerns addressed in the EtD framework.6
Evidence Based
Differentiated Benefit
Get more information on ZILRETTA in your office or your inbox. Schedule a rep visit or sign up for email updates to be sure you have the latest information on new developments and support for you, your staff, and your patients.
REQUEST A REP/EMAIL SIGN-UPJohn Richmond, MD, reviews the clinical data for ZILRETTA and moderates a dynamic panel with Ira Evans, MD, Scott Sigman, MD, and Jason Rand, MD.
Watch The VideoBECOME A PLAYER
We’ve deployed the Z Team, a dedicated patient concierge program to connect patients with healthcare providers who have experience with ZILRETTA. Register to see if you are eligible to be part of our Provider Locator tool and let our Z Team members bring interested patients directly to you.
REGISTER YOUR OFFICE TODAYGET YOUR PATIENTS STARTED
We work within your established process and provide comprehensive access support at every step with FlexForward®
SEE HOW IT WORKSReferences:
X